Stay updated on Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Sign up to get notified when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.

Latest updates to the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedUpdated the Publications section to state that PubMed publications are automatically filled in from PubMed, and updated the revision label from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check19 days agoChange DetectedThe page no longer displays the government funding lapse notice. This change does not affect any study details, eligibility criteria, or locations.SummaryDifference0.4%

- Check33 days agoChange DetectedAdds sponsor/collaborator institutions—Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine—and a new 'Helpful Links Provided by' section.SummaryDifference0.6%

- Check40 days agoChange DetectedThe affiliations for Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, and for Washington University School of Medicine, have been removed. The 'Helpful Links Provided by' section is no longer displayed.SummaryDifference0.2%

- Check62 days agoChange Detected- Added a government-funding notice about potential delays and updated operating status guidance, and a major version bump to v3.2.0. - Removed the previous version tag v3.1.0.SummaryDifference3%

- Check69 days agoChange DetectedRemoved a specific resource entry for a disease and updated the page version to v3.1.0.SummaryDifference0.5%

Stay in the know with updates to Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ramucirumab+Pembrolizumab in Recurrent Head & Neck Cancer Clinical Trial page.